Health Trials

Hematological Malignancy (Leukemia- Lymphoma)

2

Review clinical trials related to Hematological Malignancy (Leukemia- Lymphoma). Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in Adult Participants With Relapsed/Refractory CD19-positive B-cell Malignant Hematological Tumors

This study is a prospective single-arm open-label clinical trial, including dose escalation and expansion phase, aims to evaluate the safety, efficacy, and cellular pharmacokinetics of GT719 Injection in relapsed/refractory CD19 positive adult B-cell non Hodgkin lymphoma (B-NHL) and B-acute lymphoblastic leukemia (B-ALL) patients. A total of 34 subjects will be enrolled in this study.

Participants needed: 34
Trial details
Phase: Early Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Grit BiotechnologyUpdated: Dec 30, 2025Locations: 1
Eligibility criteria

1. Voluntarily enrolled in the study, signed an informed consent form, willing a... [+15]

1. Participants with a history of central nervous system (CNS) leukemia/lymphoma... [+23]

Read more
Status: Recruiting

GT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Malignancies

This study is a prospective single-arm open-labled phase I/II clinical trial, including dose escalation and expansion phase, aims to evaluate the safety, efficacy, and cellular pharmacokinetics of GT719 Injection in relapsed/refractory CD19 positive adult B-cell non Hodgkin lymphoma (B-NHL) and B-acute lymphoblastic leukemia (B-ALL) patients. A total of 46 subjects (anticipated) will be enrolled in this study.

Participants needed: 46
Trial details
Phase: Phase 1, Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Grit BiotechnologyUpdated: Sep 16, 2025Locations: 1
Eligibility criteria

Voluntarily enrolled in the study, signed an informed consent form, and willing... [+2]

Primary immunodeficiency. [+2]

Read more